You are here

Global TB Guidelines, Policies and Plans

Treatment of Drug-Resistant Tuberculosis - An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Nov 2019
Treatment of Drug-Resistant Tuberculosis - An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Background:

The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.

WHO Global Tuberculosis Report 2019

Oct 2019
WHO Global Tuberculosis Report 2019

Tuberculosis (TB) is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent (ranking above HIV/AIDS). It is caused by the bacillus Mycobacterium tuberculosis, which  is  spread when people who are sick with TB expel bacteria into the air; for example, by coughing. It typically affects the lungs (pulmonary TB) but can also affect other sites (extrapulmonary TB).

WHO guidelines on tuberculosis infection prevention and control - 2019 update

Mar 2019
WHO guidelines on tuberculosis infection prevention and control - 2019 update

The World Health Organization has just issued updated WHO guidelines on TB infection prevention and control. These guidelines outline a new evidence-based framework that promotes the implementation of an integrated package of Infection Prevention & Control (IPC) interventions based on administrative, engineering, and respiratory protection controls. This will contribute to cutting transmission and reducing the burden of TB illness and death to reach the global targets of the End TB Strategy and the political declaration of the UN High Level meeting on TB.

Management of Multidrug-Resistant Tuberculosis in Children: A FIELD GUIDE - Sentinal Project

Feb 2019
Sentinal Project - Management of Multidrug-Resistant Tuberculosis in Children: A FIELD GUIDE

Multidrug-resistant (MDR) tuberculosis (TB) is a growing global health crisis; MDR-TB is defined TB disease caused by strains of Mycobacterium tuberculosis with in vitro resistance to at least isoniazid and rifampicin, and it is estimated there are more than five million people infected and sick with drug-resistant forms of TB in the world today. With the increasing use of the Xpert MTB/RIF® to detect both TB and rifampicin resistance, the term “rifampicin-resistant TB” (RR-TB) is increasingly used as well.

The Union Management of Diabetes Mellitus-Tuberculosis - A Guide to the Essential Practice

Jan 2019
The Union Management of Diabetes Mellitus-Tuberculosis - A Guide to the Essential Practice

Diabetes mellitus (DM) increases the risk of tuberculosis (TB) by 2–3 times and increases the risk of adverse TB treatment outcomes. TB causes “stress-induced hyperglycaemia” and this can make the management of DM more difficult. A published “Collaborative Framework for the Care and Control of Tuberculosis and Diabetes” can guide policy makers and implementers in combatting the epidemics of both diseases.

Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment

Dec 2018
Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment

Patients on treatment for drug-resistant tuberculosis (DR-TB) face many challenges, most notably difficult side effects such as nausea, hearing loss and fatigue that may impact the patient’s quality of life, capacity to work and ability to continue activities of daily living. Recent studies have identified medication side effects as a major factor for patients stopping treatment prematurely. The 2017 WHO Global TB Report noted a continued crisis related to treatment outcomes for drug-resistant TB with only 54% of patients successfully completing treatment in 2014.

Political declaration of the UN high-level meeting

Oct 2018

We, Heads of State and Government and representatives of States and Governments, assembled at the United Nations in New York on 26 September 2018, with a dedicated focus for the first time on the global tuberculosis epidemic, reaffirm our commitment to ending the tuberculosis epidemic globally by 2030 in line with the Sustainable Development Goals target, commit to ending the epidemic in all countries, and pledge to provide leadership and to work together to accelerate our national and global collective actions, investments and innovations urgently to fight this preventable and treatable disease, affirming that tuberculosis, including its drug - resistant forms, is a critical challenge and the leading cause of death from infectious disease...

Roadmap towards ending TB in children and adolescents - WHO

Sep 2018
Roadmap towards ending TB in children and adolescents

The 2018 United Nations General Assembly High-Level Meeting (HLM) on Tuberculosis and the current revision of the Roadmap for childhood tuberculosis together present an important moment to consolidate and advance advocacy, commitment, resource mobilization and joint efforts by all stakeholders to provide health care and address the burden of TB among children.

WHO Global Tuberculosis Report 2018

Sep 2018

On 26 September 2018, the United Nations (UN) will hold its first high-level meeting on tuberculosis (TB), at its headquarters in New York.

The title of the meeting – United to End TB: An Urgent Global Response to a Global Epidemic – highlights the need for immediate action to accelerate progress towards the goal of ending the TB epidemic by 2030.

WHO Global Tuberculosis Report 2017

Dec 2017

WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO’s Member States and broader development goals set by the United Nations. 

The data in this report are updated annually.

Guide to Develop an Action Plan on Public-Private Mix - WHO & USAID

Dec 2017

The importance of engaging all providers in tuberculosis (TB) care and prevention has been recognized for well over a decade. Over 4 million people with TB are missed each year by health systems and therefore do not get the care they need and deserve. A large proportion of these patients, especially in Asia, are diagnosed and managed in the private sector or unengaged public sector, but not notified to national health systems.

WHO Global Tuberculosis Report 2016

Oct 2016

WHO has published a global TB report every year since 1997.

The Sustainable Development Goals (SDGs) for 2030 were adopted by the United Nations in 2015. One of the targets is to end the global TB epidemic. The WHO End TB Strategy, approved by the World Health Assembly in 2014, calls for a 90% reduction in TB deaths and an 80% reduction in the TB incidence rate by 2030, compared with 2015.

WHO Implementing the end TB strategy: the essentials

Jan 2016

2016 is the first year of implementation of the WHO End TB Strategy in the context of the United Nations Sustainable Development Goals Agenda, both of which include the aim of ending the TB epidemic. To support the work ahead, the World Health Organization’s Global TB Programme has developed operational guidance, The Essentials, for effective adaptation and implementation of the new Strategy as was requested by Member States during the 2014 World Health Assembly. 

National Action Plan For Combating Multidrug-Resistant Tuberculosis

Jan 2016

Tuberculosis (TB) is the leading infectious disease killer globally, and in 2015 it claimed the lives of 1.8 million people. The deadly disease caused by Mycobacterium tuberculosis (MTB) is transmitted through the air from person to person and it occurs in the U.S. and around the world. TB is curable, but inappropriate treatment can lead to multidrug-resistant TB (MDR-TB), which is resistant to the two most effective anti-TB drugs, and extensively drug-resistant TB (XDR-TB), which is often deadly. An MDR-TB outbreak in the U.S.

WHO Guidelines on the management of latent tuberculosis infection

Dec 2015
WHO Guidelines on the management of latent tuberculosis infection

Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active TB. A direct measurement tool for M. tuberculosis infection in humans is currently unavailable. The vast majority of infected persons have no signs or symptoms of TB but are at risk for developing active tuberculosis (TB) disease. This can be averted by preventive treatment.

Global Plan To End TB - Stop TB Partnership

Nov 2015

The Global Plan to End TB provides a roadmap for the fight against TB for a five-year period.

The Partnership has launched the new Global Plan to End TB 2016 - 2020. The Plan will provide a costed blue-print for how global TB efforts can become significantly more ambitious and effective over the next five years by dramatically changing the way TB programs are run. It will outline what it takes to set the world on the right track to reach the goals set in the post-2015 Global TB Strategy.

The End TB Strategy - WHO

May 2014

WHO’s declaration of tuberculosis as a global public health emergency in 1993 ended a period of prolonged global neglect.

Together, the subsequent launch of the directly observed treatment, short course (DOTS) strategy; inclusion of tuberculosis-related indicators in the Millennium Development Goals; development and implementation of the Stop TB Strategy that underpins the Global Plan to Stop TB 2006–2015; and adoption of resolution WHA62.15 on the prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis by the Sixty-second World Health Assembly have all helped to accelerate the global expansion of tuberculosis care and control.

Subscribe to Global TB Guidelines, Policies and Plans